As technological advances unlock a more nuanced understanding of disease – and exciting opportunities for personalised medicine – some cancers are now being redefined as rare diseases.
Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.
Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib, its experimental drug for brain cancer.
NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in final draft guidance.
Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start clinical testing in lymphoma patients later this year.